Ultragenyx Pharmaceutical (RARE) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 31.42% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -6.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.05% |
| Dec 31, 2025 | -4.32% |
| Sep 30, 2025 | 0.02% |
| Jun 30, 2025 | -13.89% |
| Mar 31, 2025 | -5.48% |
| Dec 31, 2024 | -4.13% |
| Sep 30, 2024 | 3.12% |
| Jun 30, 2024 | 3.58% |
| Mar 31, 2024 | -2.99% |
| Dec 31, 2023 | 15.22% |
| Sep 30, 2023 | -32.94% |
| Jun 30, 2023 | -49.75% |
| Mar 31, 2023 | -14.97% |
| Dec 31, 2022 | -1.70% |
| Sep 30, 2022 | 0.28% |
| Jun 30, 2022 | 7.15% |
| Mar 31, 2022 | -12.92% |
| Dec 31, 2021 | -7.26% |
| Sep 30, 2021 | -4.55% |
| Jun 30, 2021 | -3.32% |
| Mar 31, 2021 | -25.02% |
| Dec 31, 2020 | -1.66% |
| Sep 30, 2020 | -1.42% |
| Jun 30, 2020 | 54.56% |
| Mar 31, 2020 | -20.99% |
| Dec 31, 2019 | -29.68% |
| Sep 30, 2019 | -43.36% |
| Jun 30, 2019 | -28.26% |
| Mar 31, 2019 | -28.69% |
| Dec 31, 2018 | -10.42% |
| Sep 30, 2018 | -29.15% |
| Jun 30, 2018 | -63.05% |
| Mar 31, 2018 | -70.60% |
| Dec 31, 2017 | -94.01% |
| Sep 30, 2017 | -71.33% |
| Jun 30, 2017 | -69.22% |
| Mar 31, 2017 | -76.66% |
| Dec 31, 2016 | -56.98% |
| Sep 30, 2016 | -65.92% |
| Jun 30, 2016 | -75.39% |
| Mar 31, 2016 | -92.80% |